PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2058595
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2058595
Lab Automation for In-Vitro Diagnostics Market size was valued at US$ 6,005.2 Million in 2025, expanding at a CAGR of 7.3% from 2026 to 2033.
Lab Automation for In-Vitro Diagnostics refers to the use of automated instruments, robotic systems, software platforms, and digital workflows to perform laboratory diagnostic testing with limited manual handling. These systems help laboratories manage activities such as sample preparation, testing, data recording, and result analysis in a more organized and efficient manner. Automation is widely used in hospitals, diagnostic centers, and research laboratories to improve testing consistency, reduce operational delays, and support large-scale clinical testing. It also assists healthcare professionals in delivering faster diagnostic information for disease detection, patient monitoring, and treatment planning across different healthcare settings.
The Lab Automation for In-Vitro Diagnostics market is developing steadily as healthcare systems worldwide continue strengthening laboratory infrastructure and digital healthcare services. The U.S. Food and Drug Administration continues expanding regulatory guidance for in-vitro diagnostics, laboratory software validation, and connected healthcare systems to support safe and reliable automated testing environments. The World Health Organization states that diagnostic services influence nearly 70% of healthcare decisions, encouraging countries to modernize laboratory operations and improve access to quality diagnostics. Governments across Asia-Pacific and the Middle East are also increasing investment in smart hospitals, molecular testing facilities, and laboratory digitalization programs, supporting broader adoption of automated analyzers, robotic sample handling systems, and integrated laboratory workflow technologies worldwide.
Lab Automation for In-Vitro Diagnostics Market- Market Dynamics
Rising demand for faster and high-volume diagnostic testing supporting market expansion
The Increasing demand for faster and high-volume diagnostic testing has become a key factor in the Lab Automation for In-Vitro Diagnostics market, as healthcare systems manage large volumes of patient samples and complex laboratory procedures. Laboratories are increasingly adopting automated analyzers, robotic sample handling systems, and digital workflow platforms to reduce manual workload and improve testing efficiency. The World Health Organization states that diagnostic results influence nearly 70% of healthcare decisions, highlighting the growing importance of reliable and timely laboratory services.
Countries across Asia and other developing healthcare regions are strengthening laboratory infrastructure and expanding access to molecular and infectious disease testing programs. Companies such as Roche and Abbott are expanding automated diagnostic platforms and integrated laboratory systems to support faster clinical testing and large-scale sample management. Increasing demand for accurate, scalable, and continuous testing operations is encouraging hospitals and diagnostic centers to modernize laboratories with automated in-vitro diagnostic technologies.
The Global Lab Automation for In-Vitro Diagnostics Market is segmented on the basis of Product Type, Application, Process Type, End User, and Region.
Under product type categories, the market varies into five types. Automated analyzers designate its participation in the Lab Automation for In-Vitro Diagnostics market due to the increasing demand for rapid, accurate, and high-volume clinical testing. Healthcare laboratories are under continuous pressure to process larger numbers of patient samples while maintaining testing consistency and reducing manual intervention. Automated analyzers help laboratories improve workflow efficiency through integrated sample handling, faster processing, and digital data management. Companies such as Roche are strengthening connected analyzer systems and intelligent laboratory automation platforms to support molecular diagnostics, immunoassays, and clinical chemistry testing. Industry reports also indicate growing adoption of automated liquid handling and analyzer technologies as laboratories modernize operations to manage complex diagnostic workloads and reduce human error in testing environments. Increasing demand for standardized diagnostic workflows, rising laboratory testing volumes, and broader adoption of digital healthcare infrastructure are encouraging hospitals and diagnostic centers to invest in advanced automated analyzer systems for routine and specialized testing applications.
Lab Automation for In-Vitro Diagnostics Market- Geographical Insights
From a global regional outlook, Asia-Pacific is forecasted to register meaningful growth in the Lab Automation for In-Vitro Diagnostics market as healthcare systems across the region continue modernizing laboratory infrastructure and expanding access to advanced diagnostic services. Governments are supporting digital healthcare programs, intelligent hospital systems, and laboratory standardization initiatives to improve testing efficiency and patient care. China is emerging as an important country within this development due to rising investment in automated clinical laboratories, infectious disease surveillance, and precision medicine programs. The country is encouraging adoption of smart healthcare technologies through healthcare modernization policies and expansion of digital hospital networks. Companies such as Mindray, Sysmex Corporation, and Fapon are strengthening automated analyzers, robotic sample handling systems, and intelligent laboratory platforms to support growing testing requirements across hospitals and diagnostic centers. The World Health Organization states that nearly 70% of healthcare decisions are influenced by diagnostic testing, while many countries are still expanding access to reliable laboratory systems and essential diagnostics. In parallel, the U.S. Food and Drug Administration continues strengthening regulatory guidance for in-vitro diagnostics, laboratory-developed tests, software validation, and electronic laboratory data integration, encouraging global manufacturers to improve automation quality and workflow reliability. These developments are encouraging healthcare providers, research institutions, and laboratory operators across the Asia-Pacific to adopt scalable and digitally connected laboratory automation technologies for faster and more standardized diagnostic testing services
South Korea Lab Automation for In-Vitro Diagnostics Market- Country Insights
South Korea is strengthening its position in laboratory automation for in-vitro diagnostics through continued investment in digital healthcare infrastructure, AI-supported diagnostics, and smart hospital programs. The ministries of Health and Welfare and Science and ICT have been backing the commercialization efforts on AI technology-driven healthcare technologies via AX-Sprint campaign. The AX-Sprint program provides funding support to clinical validation and hospital system-integration projects. The Korean government recently revealed that it plans to spend around 940 billion won on the research and development of advanced medical devices until 2032. The country is also witnessing active participation from companies such as Seegene, Sysmex Corporation, and Samsung Medical Center in expanding automated molecular diagnostics and laboratory data integration technologies. South Korea is building secure medical data-sharing platforms and AI-specialized hospital networks to improve workflow automation and diagnostic accuracy across healthcare institutions. Government-backed projects such as Doctor Answer 2.0 are supporting development of AI medical software for multiple diseases through collaborations involving hospitals and ICT firms. These developments are encouraging broader adoption of connected and automated diagnostic laboratories throughout the country.
In response to the rising need for faster diagnostic turnaround, digital laboratory supervision, and high-throughput testing, companies operating in the Lab Automation for In-Vitro Diagnostics market are firming their technological abilities through automation upgrades, software integration, and strategic associations. Roche, Abbott, Siemens Healthineers, Danaher Corporation, and Labcorp are some of the key players who have implemented automated analyzers, AI-based laboratory testing systems, and integrated diagnostic devices to enhance workflow accuracy and sample handling efficiency.
In 2025, Siemens expanded its laboratory software capabilities through the acquisition of Dotmatics, while Abbott announced the acquisition of Exact Sciences to strengthen automated molecular diagnostics and oncology testing solutions. Companies are also investing in robotic sample handling, cloud-based laboratory data systems, and integrated testing platforms to support hospitals, clinical laboratories, and research institutions seeking efficient and standardized diagnostic operations.
In January 2026, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to advance AI-enabled scientific instruments and improve laboratory automation performance in diagnostics and research facilities. The collaboration strengthened AI-driven laboratory automation capabilities, supporting faster diagnostics, smarter workflows, and improved operational efficiency in research laboratories.
In October 2025, ARCHIMED Diagnostics finalized the acquisition of ARK Diagnostics to support expansion in automated immunoassay testing and therapeutic drug monitoring solutions. The acquisition expanded automated diagnostic testing capabilities, enhancing therapeutic monitoring efficiency and supporting broader adoption of advanced immunoassay technologies.